Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | SCN4A | P35499 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | PI4KA | P42356 | 3/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594896 | 1.00 | RAB9A (0.41) | RAB9ASMN1; SMN2NPC1SCN4AMAPT | |
| SCHEMBL11999657 | 0.79 | RAB9A (0.40) | RAB9ASMN1; SMN2NPC1SCN4AMAPT | |
| SCHEMBL2666929 | 0.78 | RAB9A (0.42) | RAB9ASMN1; SMN2NPC1SCN4AMAPT | |
| SCHEMBL30858903 | 0.75 | AXL (0.48) | RAB9ASMN1; SMN2NPC1SCN4AMAPT | |
| SCHEMBL558903 | 0.75 | AXL (0.48) | RAB9ASMN1; SMN2NPC1SCN4AMAPT | |
| SCHEMBL31109671 | 0.75 | RAB9A (0.48) | RAB9ASMN1; SMN2NPC1SCN4AMAPT | |
| SCHEMBL30136461 | 0.75 | RAB9A (0.40) | RAB9ASMN1; SMN2NPC1SCN4AMAPT | |
| SCHEMBL5533108 | 0.75 | RAB9A (0.48) | RAB9ASMN1; SMN2NPC1SCN4AMAPT | |
| SCHEMBL113113 | 0.75 | RAB9A (0.40) | RAB9ASMN1; SMN2NPC1SCN4AMAPT | |
| SCHEMBL30526769 | 0.75 | GAA (0.48) | RAB9ASMN1; SMN2NPC1SCN4AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114437113-B | Thiazolopyridine cyclotriazole compound, and preparation method and application thereof | 西安交通大学 | 2023-05-02 | — | — | CN | claimed |
| CN-114437113-A | Thiazolopyridine ring-linked triazole compound and preparation method and application thereof | 西安交通大学 | 2022-05-06 | — | — | CN | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| EP-4727938-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2025-09-23 | — | — | US | disclosed |
| US-12415816-B2 | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | BEIGENE, LTD. (KY) | 2025-01-23 | — | — | US | disclosed |
| WO-2024259121-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2024-12-19 | — | — | WO | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2009129211-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20080318948-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| WO-2008119734-A2 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| EP-1934180-A2 | 3-CYCLYL-2-(4-SULFAMOYL-PHENYL)-N-CYCLYL-PROPIONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF IMPAIRED GLUCOSE TOLERANCE AND DIABETES | Novartis AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| WO-2007041365-A2 | 3-CYCLYL-2- (4-SULFAMO YL-PHENYL) -N-CYCLYL-PROPIONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF IMPAIRED GLUCOSE TOLERANCE AND DIABETES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | TNF, LITAF, PNLIP | RAB9A 2203/4885SMN1; SMN2 697/4885NPC1 122/4885 |
| US-12415816-B2 | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof | JAK2, JAK1, JAK3 | RAB9A 3000/4885SMN1; SMN2 4156/4885NPC1 2801/4885 |
| US-20080318948-A1 | Organic Compounds | GCK, GCKR, SLC2A2 | RAB9A 4771/4885SMN1; SMN2 4275/4885NPC1 1813/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | RAB9A 759/4885SMN1; SMN2 65/4885NPC1 1215/4885 |
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | RAB9A 3465/4885SMN1; SMN2 2374/4885NPC1 2057/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | RAB9A 519/4885SMN1; SMN2 3529/4885NPC1 2436/4885 |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | POLQ, POLK, POLI | RAB9A 4281/4885SMN1; SMN2 4018/4885NPC1 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.